Table 1. Patient characteristics of the training cohort and external validation cohort.
| Variables | Training cohort (n=243) | External validation cohort (n=80) | P value |
|---|---|---|---|
| Age (years) | 70.00 (65.00, 76.00) | 69.50 (64.00, 75.25) | 0.685 |
| tPSA (ng/mL) | 14.47 (8.48, 32.50) | 21.44 (12.68, 70.21) | 0.001* |
| fPSA (ng/mL) | 1.95 (1.29, 3.78) | 2.83 (1.46, 6.65) | 0.039* |
| f/t PSA | 0.13 (0.10, 0.19) | 0.10 (0.07, 0.16) | 0.004* |
| Pathologic specimen type | 0.527 | ||
| Surgical specimen | 107 (44.0) | 32 (40.0) | |
| Biopsy specimen | 136 (56.0) | 48 (60.0) | |
| Pathological results | 0.146 | ||
| No cancer | 65 (26.7) | 14 (17.5) | |
| Gleason score 6 | 12 (4.9) | 7 (8.8) | |
| Gleason score ≥7 | 166 (68.3) | 59 (73.8) | |
| Lesion location | 0.604 | ||
| PZ | 168 (69.1) | 57 (73.1) | |
| TZ and AFS | 75 (30.9) | 23 (28.8) | |
| ADC (10 mm/s) | 913.05 (809.99, 1,063.30) | 921.82 (802.52, 1,161.55) | 0.449 |
| T1 (msec) | 1,292.64 (1,214.20, 1,380.03) | 1,269.98 (1,189.08, 1,378.11) | 0.657 |
| T2 (msec) | 84.02 (78.15, 91.12) | 86.43 (79.11, 94.15) | 0.16 |
| PD (pu) | 81.54 (79.94, 82.76) | 79.42 (77.06, 81.45) | <0.001* |
| PI-RADS | 0.763 | ||
| PI-RADS 3 | 60 (24.7) | 23 (28.8) | |
| PI-RADS 4 | 59 (24.3) | 19 (23.8) | |
| PI-RADS 5 | 124 (51.0) | 38 (47.5) |
Data were expressed as median (first quartile, third quartile) or number (percentage). *, statistically significant. tPSA, total prostate-specific antigen; fPSA, free prostate-specific antigen; f/t PSA, free/total prostate-specific antigen ratio; PZ, peripheral zone; TZ, transition zone; AFS, anterior fibromuscular stroma; ADC, apparent diffusion coefficient; T1, longitudinal relaxation time; T2, transverse relaxation time; PD, proton density; PI-RADS, Prostate Imaging-Reporting and Data System.